Health & Wellness Blog - Page 69

Study Explores Plant-Based Platform for Oral GLP-1 Therapies

A pioneering study led by Henry Daniell at Penn Dental Medicine has engineered lettuce chloroplasts to produce functional exenatide and lixisenatide, offering a plant-based path to oral GLP-1 therapies. This approach addresses key barriers like stomach degradation and high costs, potentially transforming diabetes and obesity treatment. Patients may soon swap weekly injections for simple lettuce-based pills.

Shotlee·Mar 6, 2026·6 min read

GLP-1 Side Effects

GLP-1 Medications Like Ozempic May Cause Hair Loss: Here's Why

Social media is buzzing with reports of hair loss among GLP-1 users on drugs like Ozempic and Wegovy. While research is emerging, experts like Yale dermatologist Dr. Sara Perkins confirm patients are noticing more shedding. Here's the science behind it and steps to address it.

Shotlee·Mar 6, 2026·6 min read

GLP-1 Medication Safety

NC Poison Control Warns GLP-1 Users to Use Caution

North Carolina Poison Control is alerting GLP-1 users to watch for common dosing mistakes after averaging one to two calls daily last year. With 80% involving administration errors for drugs like Ozempic, Wegovy, and Mounjaro, most cases were mild but highlight real risks. Discover symptoms, prevention strategies, and FDA advice on compounded GLP-1 drugs.

Shotlee·Mar 3, 2026·5 min read

GLP-1 Medications

Wegovy and Ozempic May Slash Deadly Heart Attack Complication Risk

Researchers from the University of Bristol and UCL have found that GLP-1 drugs like Wegovy and Ozempic could dramatically reduce the risk of 'no-reflow,' a deadly complication affecting up to half of heart attack patients. By relaxing tiny blood vessels, these medications may prevent further heart damage even if given by paramedics on-site. This study opens doors for repurposing popular obesity and diabetes treatments in emergency cardiac care.

Shotlee·Mar 3, 2026·6 min read

GLP-1 Medications

Joan Collins, 92, Rejects Ozempic Over 'Disastrous Faces' and Needles

At 92, actress Joan Collins declares she'd 'never dream' of using Ozempic, citing 'too many disastrous faces' and her aversion to needles. This sparks discussion as Kelly Osbourne confronts cruel commentary on her look at the Brit Awards. Learn the medical context behind these celebrity views on GLP-1 drugs.

Shotlee·Mar 3, 2026·5 min read

GLP-1 Medications

Zydus' ZYOG1: Oral GLP-1 Ahead of Ozempic by 15 Years

Fifteen years before Ozempic sparked the GLP-1 revolution, Zydus Lifesciences in India developed ZYOG1, a promising oral GLP-1 agonist. Showing preclinical benefits for glucose control, weight loss, and a clean safety profile, it earned phase I trial approval in 2010—but was shelved amid high costs. This untold story highlights India's early edge in peptide therapy.

Shotlee·Mar 3, 2026·5 min read

GLP-1 Medications

How GLP-1s Helped a Rhode Island Mom Get Sober After Alcoholism

A Rhode Island mother battled alcoholism for years, losing custody of her son—until GLP-1 drugs like Wegovy changed everything. In a pilot program at Open Doors transitional home, Gina Roberts stopped her cravings, got sober for two years, and rebuilt her life. Addiction specialists share why these weight-loss meds show promise for addiction recovery.

Shotlee·Mar 3, 2026·5 min read

GLP-1 Medications

Glenmark to Launch Affordable Semaglutide, Joining Indian Peers

Glenmark Pharmaceuticals is gearing up to launch affordable versions of semaglutide, the blockbuster GLP-1 drug for diabetes and obesity, later this month. This move intensifies competition among Indian drugmakers like Sun Pharma and Dr Reddy's following the March 21 patent expiry. With prices potentially half those of innovators, millions of patients stand to gain better access.

Shotlee·Mar 3, 2026·5 min read

GLP-1 Medications

Semaglutide May Double nAMD Risk in Older Adults: Study

New research from the University of Toronto reveals that older adults with diabetes taking semaglutide (Ozempic and Wegovy) face more than double the risk of neovascular age-related macular degeneration (nAMD), a severe form of vision loss. The study, published in JAMA Ophthalmology, highlights increased risks with longer use and certain comorbidities. Patients should prioritize regular eye exams to catch issues early.

Shotlee·Mar 3, 2026·5 min read

Latest Articles

Latest Articles

Study Explores Plant-Based Platform for Oral GLP-1 Therapies

GLP-1 Medications Like Ozempic May Cause Hair Loss: Here's Why

NC Poison Control Warns GLP-1 Users to Use Caution

Wegovy and Ozempic May Slash Deadly Heart Attack Complication Risk

Joan Collins, 92, Rejects Ozempic Over 'Disastrous Faces' and Needles

Zydus' ZYOG1: Oral GLP-1 Ahead of Ozempic by 15 Years

How GLP-1s Helped a Rhode Island Mom Get Sober After Alcoholism

Glenmark to Launch Affordable Semaglutide, Joining Indian Peers

Semaglutide May Double nAMD Risk in Older Adults: Study

Latest Articles

Study Explores Plant-Based Platform for Oral GLP-1 Therapies

GLP-1 Medications Like Ozempic May Cause Hair Loss: Here's Why

NC Poison Control Warns GLP-1 Users to Use Caution

Wegovy and Ozempic May Slash Deadly Heart Attack Complication Risk

Joan Collins, 92, Rejects Ozempic Over 'Disastrous Faces' and Needles

Zydus' ZYOG1: Oral GLP-1 Ahead of Ozempic by 15 Years

How GLP-1s Helped a Rhode Island Mom Get Sober After Alcoholism

Glenmark to Launch Affordable Semaglutide, Joining Indian Peers

Semaglutide May Double nAMD Risk in Older Adults: Study